GLP-1 drug for early type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 50 years old
- Your body mass index (BMI) is between 18 and 31 (for adults) or in the 5th to 95th percentile for your age (for children)
- You have either Stage 2 type 1 diabetes (at least two diabetes-related antibodies and abnormal blood sugar levels) and have already received TZIELD® (teplizumab), or you have been newly diagnosed with early Stage 3 type 1 diabetes (within the last 8 weeks)
- You are not taking any other diabetes medications, including insulin, at the start of the study
- You have no history of pancreatitis, gastroparesis, or a family history of medullary thyroid cancer
- You are not pregnant or going through menopause, and you do not smoke
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This trial tests a medicine called a GLP-1 receptor agonist (like Ozempic) to see if it can help people with very early type 1 diabetes (stage 1) keep their insulin-making cells working longer. You may be a good fit if you have stage 1 type 1 diabetes and haven't needed insulin yet.
This trial tests a new GLP-1 receptor agonist to improve blood sugar control in people with type 2 diabetes. It may be an option if you haven't used a similar drug in the last three months and your medical records are complete.
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.